Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children
Autor: | Vesna Grivcheva-Panovska, Markus Magerl, Henriette Farkas, Avner Reshef, Stephen Fritz, Dumitru Moldovan, Bruno Giannetti, Aharon Kessel, Vaclava Gutova, Anurag Relan, Shmuel Kivity, Maria Klimaszewska-Rembiasz |
---|---|
Rok vydání: | 2019 |
Předmět: |
Male
medicine.medical_specialty complement C1 inactivator proteins Adolescent complement C1s Visual analogue scale Immunology Phases of clinical research hereditary angioedema type I and type II recombinant proteins 03 medical and health sciences HUMAN C1-ESTERASE INHIBITOR 0302 clinical medicine Clinical Protocols Symptom relief Internal medicine medicine Humans Immunology and Allergy Drug Dosage Calculations 030212 general & internal medicine Adverse effect child Angioedema business.industry angioedema Body Weight Angioedemas Hereditary Original Articles medicine.disease Confidence interval Treatment Outcome 030228 respiratory system Child Preschool Others Pediatrics Perinatology and Child Health Hereditary angioedema Administration Intravenous Female Original Article medicine.symptom business Complement C1 Inhibitor Protein hereditary |
Zdroj: | Pediatric Allergy and Immunology |
ISSN: | 1399-3038 0905-6157 |
DOI: | 10.1111/pai.13065 |
Popis: | Background Attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency (C1‐INH‐HAE) usually begin during childhood or adolescence. However, limited data are available regarding indications and modalities of treatment of children. This study evaluated recombinant human C1‐INH (rhC1‐INH) for HAE attacks in children. Methods This open‐label, phase 2 study included children aged 2‐13 years with C1‐INH‐HAE. Eligible HAE attacks were treated intravenously with rhC1‐INH 50 IU/kg body weight (maximum, 4200 IU). The primary end‐point was time to beginning of symptom relief (TOSR; ≥20 mm decrease from baseline in visual analog scale [VAS] score, persisting for two consecutive assessments); secondary end‐point was time to minimal symptoms (TTMS |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |